Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1982 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
Printed in Switzerland by Buchdruckerei ‘Der Bund’ Bern
ISBN 3-8055-3470-1

Contents

Introduction
K. Ishizaka, Baltimore, Md 1
Mouse IgE
S.B. Lehrer; B.E. Bozelka, New Orleans, La 8
Introduction 9
Why Mouse IgE? 9
Historical Background 10
IgE Biosynthesis 11
Cellular Interactions 11
Site of Synthesis 12
Stimulation of IgE Production 13
Antigen 13
Adjuvants 13
Parasite Infection 14
Non-Specific Methods 14
Suppression of Reaginic Antibody Production 15
Suppressor Cells 15
Tolerance 16
Idiotype Suppression 17
Isotype Suppression 17
Other Mechanisms 20
Ontogeny 20
IgE Isolation 21
IgE from Serum and Ascites Fluid 21
Source of IgE 21
Detection of IgE 23

Contents VI

Purification of IgE 24
IgE Hybridomas 30
IgE Properties 33
Physicochemical Properties 33
Immunoochemical Properties 34
Biological Properties 35
Biological Significance of IgE 36
Allergic Reactions 36
Parasite Infection 37
Neoplasia 37
Future Direction 38
Acknowledgements 39
References 39

IgE and Ig2a Isotypes in the Rat
H. Bazin; R. Pauwels, Brussels/Ghent 52

Historical Background 53
Rat Plasmacytoma Tumours 53
Introduction 53
Origin of the LOU Strain 55
Ileocaecal Malignant Immunocytomas 56
Biosynthesis of Rat Monoclonal Immunoglobulins 59
Production of IgE Monoclonal Immunoglobulins 59
Purification of Normal or Monoclonal IgE 61
Hybridomas 63
Antiserum to Rat IgE 63
Purification of Normal or Monoclonal IgG2a 64
Antiserum to Rat IgG2a 64
Physico-Chemical Properties of Rat IgE 64
Physico-Chemical Properties of Rat IgG2a 66
Biological Properties of Rat IgE 67
Measurement of IgE 68
Biological Properties of Rat IgG2a 71
Measurement of IgG2a 72
Regulation of IgE Production 73
Ontogeny 73
Soluble Factors Implicated in the IgE Production 79
Localization of Rat IgE Cells 82
Effect of Antigen on IgE Synthesis 83
Effect of Adjuvant on the IgE Antibody Response in the Rat 86
Effect of Age on the IgE Antibody Response in Rats 88
Genetic Control of the IgE Immune Response 89
Regulation of IgG2a Production 93
References 94

Contents VII

IgE Antibody Responses in vitro: from Rodents to Man
D.H. Katz, La Jolla, Calif 105

Introduction 105
Variations in Systems Employed for in vitro IgE Synthesis 106
Synthesis of IgE by Cultured Rabbit Lymphoid Cells 107
In vitro Stimulation of Rat Lymphoid Cells To Become IgE-Producing Cells 108
In vitro Biosynthesis of IgE by Cultured Mouse Lymphoid Cells 110
In vitro Biosynthesis of IgE by Human Peripheral Blood Mononuclear Cells 114
Culture Systems in which PWM Failed To Stimulate IgE Synthesis 115
Culture Systems in which PWM Stimulated IgE Synthesis 118
Explanations for the Conflicting Findings on the Ability of PWM To Stimulate
Human IgE Synthesis in vitro 125
Stimulation of Human IgE Synthesis in vitro by Soluble Antigen or a
Mixture of Soluble Antigen plus PWM 126
Lymphocytes Expressing Specific Fc Receptors for IgE (FcRe) 130
Soluble Factors Regulating IgE Responses in vitro 136
IgE B Cell Generating Factor Derived from Rat Lymphoid Cells 137
Regulatory Factors with Binding Affinity for IgE 139
Serum-Derived Suppressive Factor of Allergy and Enhancing Factor of Allergy 144
Conclusions 151
Acknowledgments 152
References 152

Suppression of IgE Antibody Responses with Tolerogenic Conjugates of Allergens and Haptens
A.H. Sehon, Winnipeg, Mani 161

Introduction 161
Current Hyposensitization Methods for IgE-Mediated Allergies 162
Brief Overview of Cellular Interactions Regulating the Antibody Response with Reference to IgE Production 165
New Strategies for the Specific Downregulation of the IgE Response 168
Use of Immunosuppressive Conjugates of Isologous y-Globulins or of Copolymers of D-Glutamic Acid and D-Lysine with Haptens and Proteins 169
Generation of Suppressor T Cells by Modified Allergens 170
Antigen-PEG Systems 171
Hapten-PVA Systems 180
Relationship between Suppression of Circulating IgE Antibodies and the State of Sensitivity of Animals Treated by Tolerogenic Conjugates 187
Suppression of Systemic Sensitivity of RAG-Sensitive Dogs Following Treatment with RAG-mPEG Conjugates 187
Suppression of Systemic Sensitivity of BPO-Sensitive Mice Following Treatment with BPO-PVA Conjugates 189

Contents VIII

Conclusions 193
Acknowledgements 194
References 194

Regulation of the IgE Antibody Response by Idiotype-Anti-Idiotype Network
K. Blaser; A.L. de Weck, Bern 203

Idiotype-Anti-Idiotype Regulation : Current State 204
Introduction 204
Regulation of the Immune Response by a Network of Idiotypes 206
Complementary Idiotypes as Receptors on B Lymphocytes 207
Complementary Idiotypes as Receptors on Subsets of T Lymphocytes 207
A Possible Regulatory Pathway for T-Dependent Anti-Hapten Responses 212
Manipulations of the Immune Response by Interaction with the Regulatory
Circuit of Complementary Idiotypes 213
Regulation of IgE Antibody Formation by the Idiotype-Anti-Idiotype Network. 220
Introduction 220
Phosphorylcholine System 221
Benzylpenicilloyl System 222
L-Glutamic Acid60-L-Alanine60-L-Tyrosine10 System 223
Azobenzenearsonate System 223
4-Hydroxy-3-Nitrophenyl-Acetyl System 223
Regulatory Effects of Actively Induced Anti-Idiotypes on the Formation of
IgE Antibodies 224
Production and Characterization of Anti-Hapten and Anti-Idiotypic
Antibodies 224
Regulatory Effects of Anti-Idiotypes in Mice Actively Immunized with
Syngeneic Antibodies 226
Regulatory Effects of Anti-Idiotypes in Guinea Pigs Actively Immunized
with Syngeneic Antibodies 236
In Man 238
Effects of Passively Administered Anti-Idiotypic Antibodies 238
In BALB/c Mice 238
In Guinea Pigs 242
In Man 243
Suppression of Antibody Response by Anti-Hapten- and Anti-Carrier Antidiotypic
Antibodies. Anaphylactogenic Properties of Anti-Idiotypic Antibodies 243
Effects of Antigen Coupled to Syngeneic Spleen Cells 245
Peculiarities of IgE Regulation in Respect to Regulation of Other Antibody
Classes and of Cell-Mediated Immunity 247
Perspectives for the Future 249
References 251

Contents IX

IgE Class-Specific Suppressor T Cells and Regulation of the IgE
Response
T. Kishimoto, Osaka 265

Introduction 265
Cells Involved in the IgE Antibody Response 266
Interaction of T and B Cells in the IgE Response 266
IgE Class-Specific Helper T Cells and Isotype-Specific Regulation of the Antibody Response 268
Induction and Characterization of IgE Class-Specific Suppressor T Cells 271
Induction of IgE Class-Specific Suppressor T Cells 271
Are IgE Class-Specific Suppressor T Cells Antigen-Specific or Non-Specific? 274
Suppression of the in vivo IgE Response by Suppressor T Cells 278
T Cell Factors Regulating the IgE Antibody Response 283
IgE Class-Specific Helper or Potentiating Factor(s) 283
IgE Class-Specific Suppressor Factor(s) 286
Target Cells of IgE Class-Specific Suppressor Factor(s) 291
IgE Class-Specific Suppressor T Hybridoma and Its Products 299
IgE-B Cells, the Target Cells of IgE Class-Specific Suppressor Factor 303
Conclusion and Future Prospects 307
Acknowledgment 310
References 310

Immunotherapy
P.S. Norman, Baltimore, Md 318

Introduction 318
‘Prophylactic Inoculations’ 319
Desensitization 320
Blocking Antibodies 320
Controlled Studies 321
Immunologic Correlates 323
IgE Antibodies 326
Specificity of Immunotherapy 327
Antibodies in Secretions 329
Clinically Useful Allergens for Immunotherapy 331
Problem Areas 333
Depot Methods 334
Cross-Linked or Polymerized Antigens 335
Lymphocyte Reactions 336
Suppression of IgE Antibodies 337
References 339